Objective:To analyze the clinical value of nutritional risk index (NRI) in assessing the prognosis of patients with multiple myeloma (MM).Methods:The clinical data from 120 patients with MM who received treatment at Xi'an International Medical Center Hospital between October 2019 and November 2020 were retrospectively analyzed. The patients were divided into a high NRI group (NRI ≥ 83.5, n = 76) and a low NRI group (NRI < 83.5, n = 44) based on their NRI values. The survival outcomes of the two groups were compared, and a receiver operating characteristic curve was used to evaluate the prognostic value of NRI in patients with MM. Results:Compared with the high NRI group, the low NRI group had a later stage according to the International Staging System, with lower proportions of patients having serum C-reactive protein (≤ 10 mg/L), hemoglobin (≤ 120 g/L), and albumin (≤ 35 g/L) [24 (54.55%) vs. 56 (73.68%), 38 (86.36%) vs. 45 (59.21%), 43 (97.73%) vs. 46 (60.53%), χ2 = 4.59, 7.21, 20.13, all P < 0.05]. The 1-year, 2-year, and 3-year survival rates in the low NRI group were significantly lower than those in the high NRI group (χ2 = 4.22, 37.51, 20.38, all P < 0.05), and the median overall survival was also significantly lower in the low NRI group (χ2 = 68.04, P < 0.05). Receiver operating characteristic curve analysis indicated that the area under the curve for NRI predicting 3-year survival in MM patients was 0.796. The predictive value was highest when NRI > 82.35, with a sensitivity of 92.98% and specificity of 53.97%. Conclusion:The NRI score can effectively assess the nutritional status of newly diagnosed MM patients and has significant clinical value for the early prediction of death within 3 years.

Objective:To analyze the clinical value of nutritional risk index (NRI) in assessing the prognosis of patients with multiple myeloma (MM).Methods:The clinical data from 120 patients with MM who received treatment at Xi'an International Medical Center Hospital between October 2019 and November 2020 were retrospectively analyzed. The patients were divided into a high NRI group (NRI ≥ 83.5, n = 76) and a low NRI group (NRI < 83.5, n = 44) based on their NRI values. The survival outcomes of the two groups were compared, and a receiver operating characteristic curve was used to evaluate the prognostic value of NRI in patients with MM. Results:Compared with the high NRI group, the low NRI group had a later stage according to the International Staging System, with lower proportions of patients having serum C-reactive protein (≤ 10 mg/L), hemoglobin (≤ 120 g/L), and albumin (≤ 35 g/L) [24 (54.55%) vs. 56 (73.68%), 38 (86.36%) vs. 45 (59.21%), 43 (97.73%) vs. 46 (60.53%), χ2 = 4.59, 7.21, 20.13, all P < 0.05]. The 1-year, 2-year, and 3-year survival rates in the low NRI group were significantly lower than those in the high NRI group (χ2 = 4.22, 37.51, 20.38, all P < 0.05), and the median overall survival was also significantly lower in the low NRI group (χ2 = 68.04, P < 0.05). Receiver operating characteristic curve analysis indicated that the area under the curve for NRI predicting 3-year survival in MM patients was 0.796. The predictive value was highest when NRI > 82.35, with a sensitivity of 92.98% and specificity of 53.97%. Conclusion:The NRI score can effectively assess the nutritional status of newly diagnosed MM patients and has significant clinical value for the early prediction of death within 3 years.